Author

S. Guettler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Woolston· 2 shared D. Cunningham· 2 shared I. Chau· 2 shared K. Fenwick· 2 shared K. von Loga· 2 shared L. J. Barber· 2 shared M. Gerlinger· 2 shared N. Starling· 2 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Woolston

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer

B. R. Challoner, A. Woolston, D. Lau, M. Buzzetti, C. Fong, L. J. Barber, G. Anandappa, R. Crux, I. Assiotis, K. Fenwick, R. Begum, D. Begum, T. Lund, N. Sivamanoharan, H. B. Sansano, , M. Gerlinger

The paper identifies three subtypes of MMR deficient colorectal cancer based on genetic and immune landscape evolution, linking them to T-cell infiltrates and checkpoint-inhibitor resistance.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology

Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase

K. Pollock, M. Liu, M. Zaleska, M. Pfuhl, I. Collins, S. Guettler

This study identifies fragment molecules targeting tankyrase's substrate-binding ankyrin repeat domains through biophysical assays, offering potential new therapeutic approaches for cancer.

bioRxiv · Mar 4, 2019Biophysics

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer

A. Woolston, K. Khan, G. Spain, L. J. Barber, B. Griffiths, R. Gonzalez Exposito, Y. Patil, S. Mansukhani, M. N. Davies, A. Furness, F. Sclafani, C. Peckitt, K. Kouvelakis, R. Ranftl, R. Begum, , M. Gerlinger

The paper analyzes genomic and transcriptomic data from CRC patients treated with cetuximab to identify resistance mechanisms and immune landscape changes during anti-EGFR therapy.

bioRxiv · Oct 19, 2018Cancer Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology